Show simple item record

FLAME: A computerized neuropsychological composite for trials in early dementia

dc.contributor.authorBrooker, H
dc.contributor.authorWilliams, G
dc.contributor.authorHampshire, A
dc.contributor.authorCorbett, A
dc.contributor.authorAarsland, D
dc.contributor.authorCummings, J
dc.contributor.authorMolinuevo, JL
dc.contributor.authorAtri, A
dc.contributor.authorIsmail, Z
dc.contributor.authorCreese, B
dc.contributor.authorFladby, T
dc.contributor.authorThim-Hansen, C
dc.contributor.authorWesnes, K
dc.contributor.authorBallard, C
dc.date.accessioned2020-08-05T14:25:14Z
dc.date.issued2020-10-14
dc.description.abstractINTRODUCTION: Sensitive neuropsychological tests are needed to improve power for clinical trials in early Alzheimer’s disease (AD). METHODS: To develop a neuropsychological composite (FLAME - Factors of longitudinal Attention, Memory and Executive Function), we assessed, 10,714 participants over the age of 50 from PROTECT with validated computerized assessments for 2 years. A factorial analysis was completed to identify the key cognitive factors in all participants, and further analyses examined sensitivity to change in people with stage 2/3 early AD according to the FDA framework. RESULTS: The FLAME composite score (speed of attention, accuracy of attention, memory and executive function) distinguished between normal cognition and stage 2/3 early AD at baseline, and was sensitive to cognitive and global/functional decline over 2 years, with the potential to improve power for clinical trials DISCUSSION: FLAME is sensitive to change, providing a straightforward approach to reduce sample size for RCTs in early AD.en_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR)en_GB
dc.identifier.citationVol. 12 (1), article e12098en_GB
dc.identifier.doi10.1002/dad2.12098
dc.identifier.urihttp://hdl.handle.net/10871/122332
dc.language.isoenen_GB
dc.publisherWiley / Alzheimer's Associationen_GB
dc.rights© 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
dc.subjectPROTECTen_GB
dc.subjectearly dementiaen_GB
dc.subjectAlzheimer’sen_GB
dc.subjectclinical trialsen_GB
dc.subjectSample Sizeen_GB
dc.subjectMCIen_GB
dc.titleFLAME: A computerized neuropsychological composite for trials in early dementiaen_GB
dc.typeArticleen_GB
dc.date.available2020-08-05T14:25:14Z
dc.descriptionThis is the final version. Available on open access from Wiley via the DOI in this recorden_GB
dc.identifier.eissn2352-8729
dc.identifier.journalAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoringen_GB
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_GB
dcterms.dateAccepted2020-07-30
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2020-07-30
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2020-08-05T08:49:18Z
refterms.versionFCDAM
refterms.dateFOA2020-10-30T14:35:14Z
refterms.panelAen_GB


Files in this item

Name:
dad2.12098.pdf
Size:
291.8Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

© 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Except where otherwise noted, this item's licence is described as © 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.